Published Date:2021-09-15 Original Link:https://www.onenessbio.com/en/news_detail59_2.htm No 1 Date of announcement 2021/09/15 Time of announcement 16:11:30 Subject Oneness announces the information about the investor’s conference of 2021 Q3. To which item it meets paragraph 12 Date of events 2021/09/22 Statement 1.Date of institutional investor conference:2021/09/22 2.Time of institutional investor conference:15:00 (GMT+8) 3.Location of institutional investor...Read More
Published Date:2021-09-14 Original Link:https://www.onenessbio.com/en/news_detail58_2.htm No 1 Date of announcement 2021/09/14 Time of announcement 17:24:13 Subject A Hong Kong patent titled “USE OF PATCHOULI EXTRACT IN THE PREPARATION OF COMPOSITIONS WITH AN ANTI-MICROORGANISM EFFECT” has been granted. To which item it meets paragraph 53 Date of events 2021/09/14 Statement 1.Date of occurrence of the...Read More
Published Date:2021-09-04 Original Link:https://www.onenessbio.com/en/news_detail56_2.htm No 2 Date of announcement 2021/09/04 Time of announcement 12:23:26 Subject The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open To which item it meets paragraph 53 Date of events 2021/09/03 Statement ...Read More
Published Date:2021-09-04 Original Link:https://www.onenessbio.com/en/news_detail55_2.htm No 1 Date of announcement 2021/09/04 Time of announcement 00:51:50 Subject Oneness decided not to proceed with FB704A phase 2 IND application in patients with severe COVID-19 based on strategic consideration To which item it meets paragraph 10 Date of events 2021/09/03 Statement 1.Product:FB704A 2.Mass production date:NA 3.Effect on...Read More
